A carregar...
JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy
Methotrexate (MTX) is recognized as the anchor drug in the algorithm treating chronic arthritis (RA, psoriatic arthritis), as well as a steroid sparing agent in other inflammatory conditions (polymyalgia rheumatica, vasculitis, scleroderma). Its main mechanism of action has been related to the incre...
Na minha lista:
| Publicado no: | J Leukoc Biol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852123/ https://ncbi.nlm.nih.gov/pubmed/31313387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/JLB.5RU0519-145R |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|